copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Abstract 5907: Pre-clinical evaluation of a novel antibody drug . . . Abstract Introduction: NaPi2b is a multi-transmembrane type II sodium-dependent phosphate transporters that regulates phosphate homeostasis in normal physiological condition [1] It is highly expressed in ovarian cancer (OC), non-small-cell lung cancer (NSCLC), and papillary thyroid cancer, with limited expression in normal tissue, making it a promising target for antibody-drug conjugates
Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC . . . The poster will provide a detailed overview of the preclinical proof-of-concept for TUB-040 The ADC candidate is directed against Napi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma Its IgG1 antibody targeting Napi2b is connected to its payload, the Topoisomerase I inhibitor Exatecan through a cleavable linker
ADC Therapeutics Announces Abstracts Accepted for Presentation at the . . . Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) - ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for
Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC . . . TUB-030 and TUB-040 demonstrate high and long-lasting anti-tumor efficacy in a range of preclinical models TUB-030 is directed against the tumor-associated antigen 5T4 which addresses a wide range of solid tumor indications; TUB-040 targets NaPi2b, a well-characterized target in ovarian and lung cancer Both candidates show a wide therapeutic window; first Phase 1 clinical evaluation to be
Abstract 1533: ZW220, a novel NaPi2b-targeting antibody drug conjugate . . . Abstract Background: NaPi2b is a multi-pass transmembrane sodium-dependent phosphate transport protein encoded by the gene SLC34A2 NaPi2b is involved in normal phosphate homeostasis and its expression is found in the lung, liver, and small intestine NaPi2b is highly expressed in ovarian carcinomas, lung adenocarcinomas, and colorectal carcinomas ZW220 is an antibody-drug conjugate (ADC
Screening Novel Format Antibodies to Design Bispecific ADCs that . . . FRα x NaPi2b Bispecific ADC Library Screen Design Proof of concept system with tentative aim of targeting tumors that express either FRα, NaPi2b, or both targets (OVCA NSCLC ) 48 bispecific ADCs produced, across 3 different valencies (1+1, 2+1, 2+2) 11 different formats (geometry and Fab scFv components) several paratopes
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate . . . - PubMed Abstract Purpose: This phase I trial assessed the safety, tolerability, and preliminary antitumor activity of lifastuzumab vedotin (LIFA), an antibody-drug conjugate of anti-NaPi2b mAb (MNIB2126A) and a potent antimitotic agent (monomethyl auristatin E)
Targeting NaPi2b in ovarian cancer - PubMed NaPi2b is a cell surface sodium-dependent phosphate transporter that regulates phosphate homeostasis under normal physiological conditions and is a lineage marker that is expressed in select cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues